These products form a unique range of NGAL animal and human antibodies, which enables researchers to focus on kidney damage throughout the drug development process. In this way they are able to bridge the gap between drug discovery, pre-clinical research and human clinical trial.
An evolving range of high quality monoclonal anti-NGAL antibodies from BioPorto is available and form the ideal complementary products to the NGAL ELISA kits and the NGAL antigens.
As such they are well suited use individually or in sandwich pairs for a wide range of immunoassay applications such as ELISA, Immunoblotting and Immunohistochemistry.
Antibodies are available to a variety of forms of NGAL derived from various different species.